

STRUCTURE THERAPEUTICS INC.

CHARTER OF THE RESEARCH AND DEVELOPMENT COMMITTEE OF THE BOARD OF DIRECTORS

PURPOSE

The purpose of the Research & Development Committee (the “*Committee*”) of the Board of Directors (the “*Board*”) of Structure Therapeutics Inc. (the “*Company*”), is to:

- review and provide advice for the Company’s research and development (“*R&D*”) programs on behalf of the Board;
- provide advice to the Board regarding the strategic direction of the Company’s R&D activities;
- identify and discuss significant emerging trends and issues in science and technology and consider the potential impact of such on the Company’s R&D; and
- provide advice to the Company’s management and to the Board in connection with the allocation, deployment, utilization of, and allocation of resources in the Company’s R&D.

COMPOSITION

Membership and Appointment

The Committee will consist of at least two members of the Board. The members of the Committee will be members of the Board appointed by, and will serve at the discretion of, the Board on the recommendation of the Nominating and Corporate Governance Committee. Vacancies occurring on the Committee will be filled by the Board. Resignation or removal of a Committee member from the Board for any reason will automatically constitute resignation or removal from the Committee.

Chairperson

The Board may designate a chairperson of the Committee (the “*Chair*”). In the absence of that designation, the Committee may designate a Chair by majority vote of the Committee members, provided that the Board may replace any Chair designated by the Committee at any time. The Chair will chair all regular sessions of the Committee and is responsible for setting the agendas for Committee meetings. In the absence of the Chair, the Committee shall select another member to preside in accordance with the Company’s Articles of Association (the “*Articles*”).

MEETINGS AND MINUTES

The Committee will meet whenever its members deem a meeting necessary or appropriate. The Committee will determine where and when to meet. All non-management directors who are not members of the Committee may attend meetings of the Committee and may participate in discussions at those meetings but may not vote. Additionally, the Committee may invite to its meetings any director, management of the Company and such other persons as it deems appropriate in order to carry out its

responsibilities. The Committee may also exclude from its meetings any persons (other than a member of the Committee) it deems appropriate in order to carry out its responsibilities.

A majority of the authorized number of members of the Committee shall constitute a quorum for the transaction of business and the act of a majority of those present at any meeting at which there is a quorum shall be the act of the Committee. In accordance with the Articles in case of an equality of votes the Chair shall have a second or casting vote.

The Committee will maintain written minutes of its meeting and regularly report to the Board on its actions and recommendations. The Committee may act by unanimous written consent; when it does so, those actions will be filed in the minute book.

Authority to Retain Advisors

The Committee shall have authority, in its sole discretion, to retain (or obtain the advice of) any special industry, technical, legal, accounting or other advisors or consultants to assist the Committee in fulfilling its responsibilities under this charter. If the Committee concludes that it must retain such advisors, it may do so and determine the compensation for such advisors at the Company's expense. The Committee may also pay any ordinary administrative expenses it deems appropriate in carrying out its duties at the expense of the Company. The Committee will have authority to require that any of the Company's personnel or outside advisors attend any meeting of the Committee or meet with any member of the Committee or any of its advisors.

Authority to Delegate Authority to Chair and Form Subcommittees

The Chair shall have the delegated authority to act on behalf of the Committee in connection with (1) approval of the retention of advisors (including negotiation and execution of their engagement letters), (2) approval of payment of expenses incurred by the Committee described in the previous paragraph and (3) as may otherwise be determined by the Committee. The Committee also may form and delegate authority to one or more subcommittees consisting of one or more of its members to the extent allowed under applicable law and The Nasdaq Stock Market, LLC ("*Nasdaq*") listing requirements.

By delegating an issue to the Chair or a subcommittee, the Committee does not surrender any authority over that issue. Although the Committee may act on any issue that has been delegated to the Chair or a subcommittee, doing so will not limit or restrict future action by the Chair or subcommittee on any matters delegated to it. Any action or decision of the Chair or a subcommittee will be presented to the full Committee at its next scheduled meeting. By approving this Charter, the Board delegates authority to the Committee with respect to these responsibilities.

Access to Company Resources

The Committee will have access to all Company books, records, facilities and personnel as deemed necessary or appropriate by any member of the Committee to discharge such member's responsibilities hereunder.

RESPONSIBILITIES AND DUTIES

The Committee's responsibilities are to review and provide advice, as described under "Purpose" above. The members of the Committee are not employees of the Company, and they do not perform management's functions. The Committee relies on the expertise and knowledge of management in carrying out its responsibilities. The Committee shall have the following responsibilities; *provided, however*, that this list of responsibilities is intended to be a guide and to remain flexible to account for changing circumstances and needs. Accordingly, the Committee may depart from or supplement such responsibilities, and establish policies and procedures, to the extent permitted by applicable law and Nasdaq listing requirements. The Board will retain the right to act on all such matters without limiting the Committee's authority, subject to compliance with applicable law and Nasdaq listing requirements.

1. **Review R&D Programs from Scientific Perspective.** Periodically review the Company's current and planned R&D and associated business development programs and initiatives and provide feedback to the Company's management on such programs and initiatives from a scientific perspective and evaluate the Company's progress in achieving its R&D goals and objectives.

2. **Strategic Recommendations to Board.** From time to time, (i) report to and advise the Board regarding the quality, direction and competitiveness of the Company's R&D programs and initiatives, (ii) provide strategic recommendations to the Board on such R&D and associated business development programs and initiatives, (iii) review, evaluate and advise the Board regarding the Company's progress in achieving its long-term strategic R&D goals and objectives, and (iv) advise the Board on the scientific, medical and R&D aspects of proposed transactions that required Board approval, such as investments, acquisitions and licenses.

3. **Recommend Experts.** Assist the Company's management, as requested, in identifying experts to provide strategic technical advice regarding the Company's R&D programs and initiatives.

4. **Review Trends and Developments.** Review and monitor significant emerging regulatory, research, scientific, and medical developments, processes, procedures, trends and competitive activity relevant to the Company's R&D strategy and clinical trial programs, including their potential impact on the Company's programs, plans and policies.

5. **Intellectual Property.** Review the Company's intellectual property portfolio and strategy related to the Company's R&D programs and initiatives.

6. **Risk Management.** Provide advice to management with respect to management's exercise of its responsibility to assess and manage risks associated with the Company's R&D activities, clinical development and intellectual property.

7. **Committee Self-Assessment.** The Committee will annually evaluate its performance, including by reviewing its compliance with this Charter.

8. **Charter Review.** The Committee shall also review and assess the adequacy of this Charter and shall recommend any proposed changes to the Board for its consideration and approval.

9. **Report to the Board.** The Committee will report regularly to the Board with respect to such matters as the Committee deems appropriate from time to time or whenever requested to do so. The Committee shall provide such recommendations to the Board as the Committee may deem appropriate. The report to the Board may take the form of an oral report by the Chair or any other member of the Committee designated by the Committee to make such report.

10. **General Authority.** The Committee shall perform such other functions and have such other powers as may be necessary or appropriate in the discharge of any of the foregoing.

Approved by the Board of Directors: March 26, 2024